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Activation of serum/glucocorticoid-induced 
kinase 1 (SGK1) underlies increased glycogen 
levels, mTOR activation, and autophagy defects 
in Lafora disease
Pankaj Kumar Singh, Sweta Singh, and Subramaniam Ganesh
Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur 208016, India
ABSTRACT Lafora disease (LD), a fatal genetic form of myoclonic epilepsy, is characterized 
by abnormally high levels of cellular glycogen and its accumulation as Lafora bodies in af-
fected tissues. Therefore the two defective proteins in LD—laforin phosphatase and malin 
ubiquitin ligase—are believed to be involved in glycogen metabolism. We earlier demon-
strated that laforin and malin negatively regulate cellular glucose uptake by preventing plas-
ma membrane targeting of glucose transporters. We show here that loss of laforin results in 
activation of serum/glucocorticoid-induced kinase 1 (SGK1) in cellular and animals models 
and that inhibition of SGK1 in laforin-deficient cells reduces the level of plasma membrane-
bound glucose transporter, glucose uptake, and the consequent glycogen accumulation. We 
also provide evidence to suggest that mammalian target of rapamycin (mTOR) activates 
SGK1 kinase in laforin-deficient cells. The mTOR activation appears to be a glucose-depen-
dent event, and overexpression of dominant-negative SGK1 suppresses mTOR activation, 
suggesting the existence of a feedforward loop between SGK1 and mTOR. Our findings in-
dicate that inhibition of SGK1 activity could be an effective therapeutic approach to suppress 
glycogen accumulation, inhibit mTOR activity, and rescue autophagy defects in LD.
INTRODUCTION
Lafora progressive myoclonus epilepsy, also known as Lafora dis-
ease (LD), is a fatal autosomal recessive disorder resulting from mu-
tation in the EPM2A gene coding for laforin phosphatase or the 
NHLRC1 gene coding for malin E3 ubiquitin ligase (Singh and 
Ganesh, 2009; Serratosa et al., 2012). The symptoms of LD include 
epileptic seizures, ataxia, psychosis, and dementia. Disease onset 
is at around 15 yr of age, with death ∼10–15 yr after onset (Ganesh 
et al., 2006; Singh and Ganesh, 2009; Serratosa et al., 2012). 
One of the pathological hallmarks of LD is the presence of 
polyglucosan inclusions, called Lafora bodies, in various tissues, 
including muscle, liver, and brain (Ganesh et al., 2006; Serratosa 
et al., 2012). These inclusions are cytoplasmic and water insoluble 
and are composed of lesser-branched forms of glycogen (Yokoi 
et al., 1968, 1975). Besides the finding of Lafora bodies, tissue gly-
cogen level is higher in LD animal models that lack laforin or malin 
(Tagliabracci et al., 2007; DePaoli-Roach et al., 2010). Therefore the 
LD proteins laforin and malin have been proposed to play critical 
roles in glycogen metabolism, and some of their possible functions 
have been demonstrated. For example, the laforin–malin complex 
prevents glycogen synthesis by promoting the degradation of gly-
cogen synthase and protein targeting to glycogen (PTG), the two 
proteins involved in glycogen metabolism, through the protea-
some (Fernández-Sánchez et al., 2003; Vilchez et al., 2007). How-
ever, the LD mouse models did not show any change in the level of 
total and/or the active form of these proteins, and therefore they 
were excluded as possible players in the glycogen buildup seen in 
LD (Tagliabracci et al., 2008; DePaoli-Roach et al., 2010; Turnbull 
et al., 2010). Laforin was shown to bind to glycogen/Lafora bodies 
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when phosphorylated at Thr-256 (Kobayashi and Cohen, 1999), and 
the active SGK1 phosphorylates glucose transporters and promotes 
their membrane abundance (Palmada et al., 2006; Jeyaraj et al., 
2007). We therefore explored the possible functional link between 
LD proteins and SGK1 by evaluating the phospho–Thr-256 level of 
SGK1 in the absence of these proteins. As shown in Figure 1A, 
knockdown of laforin or malin resulted in a significant increase in the 
level of the phosphorylated SGK1 as compared with the control set, 
whereas the total level of SGK1 is unchanged. The efficiency of the 
knockdown construct used is well established (Singh et al., 2012a,b) 
and was further validated in a number of experiments performed in 
the present study (see Supplemental Figure S1 and Figures 1–6). 
Next we examined the level of SGK1 in laforin-deficient mice 
(Ganesh et al., 2002). In our previous study, we demonstrated the 
enrichment of glucose transporter 1 (Glut1) and Glut4 proteins in the 
plasma membrane fraction of skeletal muscle tissue of laforin-defi-
cient mice (Singh et al., 2012a). Therefore we wanted to check the 
phosphorylation levels of SGK1 in laforin-deficient mice as well. 
As shown in Figure 1B, the phospho-SGK1 level was significantly 
higher in the skeletal muscle tissue of laforin-deficient mice, further 
suggesting that loss of laforin (or malin) would result in increased 
phosphorylation of SGK1 and that SGK1 might be overactive in LD 
tissues. The specificity of SGK1 antibodies (total and phospho forms) 
was established by knocking down SGK1 using short hairpin RNA 
interference (shRNAi; Supplemental Figure S1, E and F).
Inhibition of SGK1 abrogates excessive glycogen buildup 
in laforin-deficient cells by decreasing level of plasma 
membrane–bound Glut1
Because loss of laforin/malin results in increased abundance of 
glucose transporters (Singh et al., 2012a) and SGK1 appears to be 
hyperactive in the laforin-deficient condition, we tested whether 
inhibition of SGK1 activity in laforin/malin-deficient cells would re-
duce the level of the plasma membrane-bound form of glucose 
transporters. As shown in Figure 2A and reported earlier (Singh 
et al., 2012a), knockdown of laforin or malin led to a significant 
increase in the level of Glut1 in the plasma membrane fraction in 
COS7 cells. We used a kinase-deficient, dominant-negative SGK1 
variant (SGK1-DN) that blocks the kinase activity of SGK1 (Amato 
et al., 2009) to test our hypothesis that blocking SGK1 activity 
prevents the enrichment of Glut1 in the plasma membrane in lafo-
rin-deficient cells. As expected, coexpression of SGK1 significantly 
reduced the level of Glut1 in the plasma membrane fraction of 
laforin-deficient cells (Figure 2A). However, no such effect was 
noted when SGK1-DN was expressed in malin-knockdown cells 
(Figure 2A). Similar observations were made when Glut1 was tran-
siently coexpressed with SGK1-DN (Figure 2B). As reported earlier 
(Singh et al., 2012a), no difference in level of Glut1 (endogenous 
or the overexpressed form) was observed when the whole-cell 
lysate was analyzed (unpublished data). SGK1 is one of the deter-
minants of cellular glucose uptake (Palmada et al., 2006; Jeyaraj 
et al., 2007). Therefore we next explored whether the increased 
glucose uptake and glycogen accumulation observed in the lafo-
rin/malin-deficient cells depends on SGK1 activity. As shown in 
Figure 2C, coexpression of SGK1-DN prevented excessive glu-
cose uptake and excessive glycogen synthesis seen otherwise in 
laforin-deficient cells. However, no such difference was noted in 
malin-knockdown cells (Figure 2C). To further confirm that the ob-
served difference in the glycogen level is indeed due to the dimin-
ished activity of SGK1, we next used a pharmacological inhibitor 
for SGK1. SGK1 requires heat shock protein 90 (HSP90) for its ac-
tivity, and inhibition of HSP90 with geldanamycin also inhibits 
(Wang et al. 2002; Chan et al., 2004; Ganesh et al., 2004) and 
dephosphorylate glycogen and other complex carbohydrates 
(Tagliabracci et al., 2007). Therefore laforin deficiency might result 
in the genesis of hyperphosphorylated glycogen as Lafora bodies. 
Besides their role in the genesis of Lafora bodies, laforin and malin 
were also shown to be involved in other cellular pathways, such as 
the ubiquitin–proteasome system (Mittal et al., 2007; Garyali et al., 
2009), the endoplasmic reticulum stress response (Vernia 
et al., 2009; Wang et al., 2013), the heat shock response (Sengupta 
et al., 2011), and RNA metabolism (Singh et al., 2012b). Studies on 
LD animal models demonstrate an increased kinase activity for the 
mammalian target of rapamycin (mTOR) and autophagic defects 
(Aguado et al., 2010; Criado et al., 2012; Puri et al., 2012). The pos-
sible links between these processes and their contributions to LD 
pathogenesis are unclear.
It is intriguing that suppression of PTG or glycogen synthase in 
laforin-deficient mice led to a normal level and form of glycogen 
(Turnbull et al., 2011a, Pederson et al., 2013). Considering that lafo-
rin is a glucan phosphatase and the suggestion that hyperphospho-
rylation of glycogen results in the genesis of Lafora bodies in LD 
tissues (Tagliabracci et al., 2007, 2008; Turnbull et al., 2010), one 
would expect that loss of laforin should favor the synthesis of abnor-
mally hyperphosphorylated glycogen since these double mutants 
lack laforin—the glucan phosphatase. In this regard it is interesting 
to note that in LD tissues, besides Lafora bodies, tissue glycogen 
was also found at higher levels (Tagliabracci et al., 2007; DePaoli-
Roach et al., 2010), suggesting that the loss of laforin may result in 
increased glycogen synthesis without altering the level and/or activ-
ity of glycogen synthase. Consistent with these observations, we 
showed that laforin and malin are negative regulators of glycogen 
synthesis and regulate cellular glucose uptake (Singh et al., 2012a). 
On the basis of these findings, we hypothesized that increased avail-
ability of intracellular substrate (glucose) contributes to excessive 
glycogen synthesis, which might eventually result in the formation of 
Lafora bodies in the absence of LD proteins (Singh et al., 2012a). 
With the discovery of autophagic defects in LD (Aguado et al., 2010; 
Criado et al., 2012; Puri et al., 2012), and given its previously char-
acterized role in glycogen degradation (Kotoulas et al., 2004), it has 
been postulated that autophagic defects might contribute to glyco-
gen accumulation in LD tissues (Puri and Ganesh, 2010; Polajnar and 
Zerovnik, 2011). The aim of the present study is to elucidate mole-
cular mechanisms favoring glycogen accumulation under a laforin-
deficient condition and investigate the possible links between 
mTOR activity, autophagy defects, and the excessive glycogen ac-
cumulation seen in laforin-deficient cells. We demonstrate here that 
loss of laforin results in the activation of the serum/glucocorticoid-
induced kinase 1 (SGK1) and that its suppression reduces the level 
of plasma membrane–bound glucose transporter, glucose uptake, 
and consequent glycogen accumulation. We also provide evidence 
to suggest that SGK1 phosphorylation is rapamycin sensitive in lafo-
rin-deficient cells and perhaps mediated by mTOR. We further show 
that inhibition of SGK1 suppresses mTOR activity and restores au-
tophagic defects in laforin-deficient cells. We propose SGK1 as a 
potential therapeutic target for the treatment of LD.
RESULTS
Loss of laforin or malin results in activation of SGK1
We recently demonstrated that loss of laforin or malin results in in-
creased abundance of glucose transporters in the plasma mem-
brane, with resultant increase in glucose uptake (Singh et al., 2012a). 
One of the factors known to regulate glucose transporters is the 
SGK1 (Palmada et al., 2006; Jeyaraj et al., 2007). SGK1 is fully active 
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Figure S2). Our repeated attempts to coim-
munoprecipitate SGK1 with the transiently 
expressed laforin or malin were not success-
ful, suggesting that SGK1 might not directly 
interact with LD proteins (unpublished data). 
It is likely therefore that loss of laforin might 
indirectly activate SGK1, possibly through 
one of the upstream kinases of SGK1. Stud-
ies identified mTOR as one of the regula-
tory kinases of SGK1 (Garcia-Martinez and 
Alessi, 2008; Hong et al., 2008), and the 
mTORC1 inhibitor rapamycin inhibits SGK1 
phosphorylation at Thr-256 (Hong et al., 
2008). Intriguingly, increased mTOR activity 
was noted in laforin-deficient mice and in 
fibroblasts derived from laforin-mutant pa-
tients (Aguado et al., 2010). We therefore 
explored whether mTOR could be the ki-
nase that phosphorylates SGK1 in the ab-
sence of laforin. To investigate this possibil-
ity, we first checked whether, in our cellular 
model, knockdown of laforin activates 
mTOR. For this, we evaluated the phospho-
rylation status of the Thr-389 residue in 
p70S6 kinase (p70S6K), one of the down-
stream substrates of mTOR and a conven-
tional marker of mTOR activity (Aguado 
et al., 2010). As shown in Figure 3A, knock-
down of laforin did not change the total 
level of p70S6K but led to an increase in the 
level of its Thr-389 phospho form, suggest-
ing the activation of mTOR in laforin-defi-
cient cells in our experimental conditions as 
well. We next explored the potential role of 
mTOR in SGK1 activation in laforin-deficient 
cells. For this, COS7 cells transiently ex-
pressing the laforin-knockdown construct 
(or a nonsilencing construct) were either 
treated or not treated with rapamycin 
(0.2 μM; 1 h), and the Thr-256 phospho 
level of SGK1 was evaluated. As shown in 
Figure 3B, rapamycin treatment led to a re-
duction in the level of phospho-SGK1 even 
in the laforin-deficient condition, suggesting that the activation of 
SGK1 in the laforin-deficient condition is likely to be mediated by 
mTORC1, one of the two functional complexes of mTOR that is 
known to be sensitive to rapamycin (Laplante and Sabatini, 2012). 
The 1-h rapamycin treatment, however, did not inhibit glycogen 
accumulation in laforin-deficient cells (Figure 3C), but when cells 
were treated with rapamycin for 24 h there was a significant reduc-
tion in the level of both Thr-256 phospho SGK1 and cellular glyco-
gen content, in control and as well as in laforin-knockdown condi-
tions (Figure 3, D and E). A reason for this could be that rapamycin 
requires a longer time to regulate physiological processes such as 
glycogen metabolism, and hence no change in glycogen could be 
detected at the end of 1-h treatment. Nonetheless, both treatments 
(1 and 24 h) led to reduction in the level of phospho p70S6K (Figure 
3F), suggesting that mTOR was suppressed in both conditions. 
Taken together, our results suggest that mTOR activation in the la-
forin-deficient state could be the primary event leading to the acti-
vation of SGK1 and the increased glycogen content seen in LD 
tissues.
SGK1 kinase activity (Belova et al., 2008). Cells transfected with 
the knockdown constructs were therefore treated or not treated 
with geldanamycin (0.2 μM, 12 h) and the cellular glycogen level 
estimated. As expected, geldanamycin treatment prevented ex-
cessive glycogen buildup but only under the laforin-knockdown 
condition (Figure 2D). Taken together, our results suggest that the 
hyperactive SGK1 might underlie excessive glycogen levels in 
laforin-deficient cells.
Phosphorylation of SGK1 in the laforin-deficient condition 
is rapamycin sensitive
The increased SGK1 phosphorylation observed in the laforin-defi-
cient state, in both cell and animal models, suggests that laforin can 
potentially be a SGK1 phosphatase. To test this possibility, we tran-
siently expressed wild-type or catalytically inactive laforin (or malin) 
in COS7 cells for 36 h, either alone or in combination (Supplemen-
tal Figure S2), and evaluated the phospho–Thr-256 level of SGK1 
by immunoblotting. None of these proteins, upon overexpression, 
altered the phospho level of endogenous SGK1 (Supplemental 
FIGURE 1: Loss of laforin or malin results in the activation of SGK1. (A) The level of SGK1 was 
measured with antibodies specific to its phospho form (anti–P-SGK1) and/or its total form 
(anti-SGK1) by immunoblotting upon partial knockdown of laforin or malin in COS7. The relative 
change the phospho level of SGK1 was plotted as a bar diagram (top) to represent the fold 
change vs. control knockdown by measuring signal intensities (densitometry analysis) of three 
independent sets. Densitometric values (fold change) of the laforin-specific band (normalized for 
tubulin) are listed below the blot (identified by an asterisk). (B) Immunoblot showing the change 
in the level of phospho-SGK1 (anti-P-SGK1) or its total level (anti-SGK1) in the skeletal muscle 
tissue of laforin-knockout mice (KO) as compared with their wild-type littermates (WT). The gel 
image shown below reveals the genotype of the animals as typed by allele-specific PCR (arrow, 
620–base pair wild-type allele; arrowhead, 430–base pair knockout allele). Bar diagram (shown 
below) depicts the fold change in the level of phospho-SGK1 in laforin-deficient muscle tissues 
by measuring signal intensities (densitometry analysis). For both A and B, γ-tubulin level served 
as loading control (**p < 0.005 vs. control; ***p < 0.0005 vs. control).
Volume 24 December 15, 2013 Role of SGK1 in Lafora disease | 3779 
FIGURE 2: SGK1 inhibition reduces plasma membrane targeting of Glut1, glucose uptake, 
and glycogen accumulation in laforin-deficient cells. Immunoblot showing the enrichment of 
endogenous Glut1 (A) or transiently expressed, green fluorescent protein–tagged Glut1 (B) in 
plasma membrane fractionation (PMF) of COS7 cells transfected with various constructs as 
indicated. Probing for caveolin, a plasma membrane protein, served as loading control. 
Expression of the dominant-negative SGK and knockdown of laforin were confirmed by 
probing the whole-cell lysate (WCL) with anti-Myc (for DN-SGK) or anti-laforin (for endogenous 
laforin) antibodies. Efficiency of malin knockdown was confirmed by semiquantitative reverse 
transcription-PCR (RT-PCR) (Supplemental Figure S1C). However, the notable increase in the 
level of laforin in malin-knockdown cells indirectly confirms the efficiency of malin knockdown, 
since laforin is an established substrate of malin. Top, bar diagram depicting the fold change in 
the level of Glut1 in the PMF by measuring signal intensities (densitometry analysis from three 
independent sets; **p < 0.005 vs. control). Densitometric values (fold change) of the laforin-
specific band (normalized for tubulin) are listed below the blot (identified by an asterisk). 
(C) Bar diagram showing the fold change in the levels of cellular glucose uptake (top) and 
intracellular glycogen level (bottom) in COS7 cells transfected with the construct coding for 
the dominant-negative form of SGK (SGK1-DN) and the knockdown construct for laforin or 
malin, as indicated. (D) Bar diagram showing the fold change in the intracellular glycogen level 
in cells treated or not treated with the SGK1 inhibitor geldanamycin in cells transiently 
transfected with the knockdown constructs as indicated. For both C and D, each bar 
represents the average of three independent experiments (*p < 0.05, **p < 0.005 vs. control; 
Student’s t test).
Glycogen accumulation in laforin-
deficient state is autophagy 
independent
Loss of laforin inhibits autophagosome for-
mation (Aguado et al., 2010). Therefore it 
has been suggested that the autophagic 
defect could also contribute to glycogen 
buildup in laforin-deficient cells (Puri and 
Ganesh, 2010), since glycogen is cleared via 
autophagy (Kotoulas et al., 2004). mTOR is 
a negative regulator of autophagy, and 
studies have shown that rapamycin treat-
ment inhibits mTOR activity and conse-
quently induces autophagy (Ravikumar 
et al., 2004). Thus reduction in the glyco-
gen level observed in rapamycin treated la-
forin-deficient cells could be due to its en-
hanced degradation via the autophagic 
pathway. To test this possibility, we first 
looked at the autophagic process in our cel-
lular model. We evaluated the level of LC3-
II, a marker for autophagosome formation. 
As shown in Figure 4A, loss of laforin led to 
a reduction in the formation of autophago-
some, as judged by the decreased level of 
the LC3-II. We next tested whether rapamy-
cin treatment could induce autophagy in la-
forin-deficient cells. Surprisingly, whereas 
rapamycin treatment led to the induction of 
autophagy in control cells, no significant ef-
fect was seen in cells transfected with the 
laforin-knockdown construct (Figure 4B). 
Therefore it could be suggested that ra-
pamycin may not induce autophagy in the 
laforin-deficient state and that the observed 
reduction in cellular glycogen level in ra-
pamycin-treated, laforin-deficient cells could 
be due to the inhibition of SGK1-mediated 
glucose uptake. To further strengthen this 
notion, we used bafilomycin A1 (BafA1), an 
antibiotic compound known to perturb the 
fusion between autophagosome and lyso-
some. BafA1 treatment did not significantly 
alter the cellular glycogen level in rapamy-
cin-treated, control knockdown cells as com-
pared with rapamycin-treated, laforin-defi-
cient cells (Figure 4C), further confirming 
that the observed effect of rapamycin on 
cellular glycogen content appears to be au-
tophagy independent.
We showed earlier that glucose depriva-
tion (a glycogenolytic condition) led to gly-
cogen breakdown even in laforin-deficient 
cells, suggesting that the glycogen degra-
dation pathway is not altered upon loss of 
laforin (Singh et al., 2012a). Glucose depri-
vation is a known inducer of autophagy 
(Kim et al., 2011), and therefore we were in-
terested in investigating whether glycogen 
degradation during glucose deprivation is 
mediated by autophagy. For this, the cells 
were glucose starved and treated or not 
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mTOR-independent mechanism could rescue the autophagy de-
fect in laforin-deficient cells. We used LiCl, which induces au-
tophagy by inhibition of inositol monophosphatase independently 
of mTOR inhibition (Sarkar et al., 2005). Of interest, as shown in 
Figure 4E, LiCl treatment (10 mM, 24 h) restored the level of LC3-II 
in laforin-knockdown cells. However, the same treatment led to an 
increase in the level of glycogen in both control and laforin-defi-
cient conditions (Figure 4E), suggesting that autophagic defects 
may not have a causal role in glycogen accumulation in laforin-
deficient cells.
treated with BafA1, and the cellular glycogen level was measured 
(Figure 4D). As shown in Figure 4D, glucose deprivation did signifi-
cantly reduce the cellular glycogen level in both control and laforin-
knockdown cells. However, blockade of autophagy with BafA1 treat-
ment (as judged by increased level of LC3-II) under the same 
conditions did not significantly prevent reduction in glycogen level, 
suggesting that changes in glycogen level in laforin-deficient cells 
are not directly connected to defects in the autophagic process.
Autophagy is also induced by mTOR-independent mecha-
nisms (Fleming et al., 2011). We therefore tested whether an 
FIGURE 3: Loss of laforin indirectly regulates SGK1 phosphorylation. (A) Immunoblot showing phospho and total levels 
of P70S6K in COS7 cells transfected with the control and laforin-knockdown construct. (B) Immunoblot showing the 
level of total and phospho-SGK1 levels in COS7 cells transfected with the control or the laforin-knockdown construct 
and treated or not treated with rapamycin (0.2 μM) for 1 h, as indicated. The knockdown efficiency was established by 
probing the blot with anti-laforin antibody. Top, bar diagram showing the fold change in the phospho SGK (N = 3; 
**p < 0.005 vs. control). (C) Bar diagram depicting cellular glycogen content under similar conditions as in B (N = 3; 
**p < 0.005 vs. control). (D) Total and phospho-SGK1 level and (E) glycogen content in control and laforin-knockdown 
cells treated with rapamycin for 24 h. Results are representative of three independent experiments and show fold 
change in glycogen level vs. control knockdown (*p < 0.05, **p < 0.005, ***p < 0.0005 vs. control; Student’s t test). 
(F) Immunoblot showing the phospho and total levels of P70S6K in COS7 cells transfected with the knockdown 
construct and treated or not treated with rapamycin, as indicated. Tubulin served as loading control for all immunoblots. 
Each bar represent the average of three independent experiments (*p < 0.05, **p < 0.005 vs. control; Student’s t test). 
The densitometric values (fold change) of the laforin-specific band (normalized for tubulin) are listed below B and D 
(identified by an asterisk).
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mTOR activation in the laforin-deficient 
condition is glucose dependent
We were next interested in understanding 
the cellular mechanism(s) that activate mTOR 
in the laforin-deficient state. mTOR regu-
lates cellular homeostasis by modulating 
various anabolic and catabolic processes. 
The activity of mTOR is regulated by several 
upstream signals, including the nutrient, 
growth factor, and the energy source (Hay 
and Sonenberg, 2004; Sengupta et al., 
2010). Growth factors regulate mTOR activ-
ity via the phosphoinositide 3-kinase (PI3K)/
AKT pathway, whereas nutrients (glucose 
and amino acids) regulate mTOR activity 
through various GTPases and the AMP-acti-
vated protein kinase (AMPK; Efeyan et al., 
2013). No alteration in PI3K/AKT pathway 
was observed in laforin-deficient cells (Sup-
plemental Figure S1D) or laforin-deficient 
mice (Puri et al., 2009). We therefore wanted 
to investigate whether a nutrient-dependent 
mechanism could be the trigger for mTOR 
activation in laforin-deficient cells. Glucose 
availability regulates mTOR activity by both 
AMPK-dependent and AMPK-independent 
mechanisms (Kimura et al., 2003; Buller 
et al., 2011). Because the intracellular AMP/
ATP ratio regulates AMPK-dependent mTOR 
activity (Kimura et al., 2003), we first investi-
gated whether loss of laforin perturbs the 
cellular AMP/ATP ratio and the AMPK activ-
ity. As shown in Figure 5A, neither cellular 
ATP content nor AMPK activity (as measured 
by level of phospho–Thr-172 AMPK) showed 
any difference in laforin-deficient cells, sug-
gesting that mTOR activation in laforin-defi-
cient cells is AMPKI independent.
Intracellular glucose availability and gly-
colytic flux regulate mTOR activity indepen-
dently of the AMPK and tuberous sclerosis 
complex (Lee et al., 2009; Buller et al., 
2011). We therefore investigated whether 
increased cellular glucose availability in la-
forin-deficient cells could be a potential 
reason for mTOR activation. To test this, we 
maintained cells transiently transfected with 
a laforin-knockdown construct or a nonsi-
lencing construct in the presence or ab-
sence of glucose for 12 h and evaluated the 
level of phospho-p70S6K (Thr-389). Indeed, 
as shown in Figure 5B, glucose deprivation 
led to a significant reduction in phospho-
p70S6K level even in the absence of laforin, 
suggesting that activation of mTOR in 
laforin-deficient state could be due to in-
creased intracellular glucose level. To fur-
ther confirm this, we treated cells transiently 
transfected with the laforin-knockdown 
construct with cytochalasin B (a glucose up-
take inhibitor) or 2-deoxyglucose (a glyco-
lytic inhibitor) for 12 h and checked the 
FIGURE 4: Glycogen accumulation in laforin-deficient cells is rapamycin sensitive but autophagy 
independent. Immunoblots showing LC3II level under control and laforin-knockdown conditions 
when cells were left untreated (A) or treated with rapamycin (B). (C) Bar diagram showing fold 
change in glycogen level in control and laforin-knockdown COS7 cells and treated with rapamycin 
for 24 h either alone or in the presence of the autophagy inhibitor bafilomycin A1 (BafA1), as 
indicated. (D) Glycogen level (top, bar diagram) in COS7 cells transfected with control or laforin-
knockdown construct and glucose starved for 12 h at 36 h posttransfection in the presence or 
absence of bafilomycin A1 treatment, as indicated. The lysates were also probed with anti-LC3 
antibody (middle) to show autophagy blockade. The bar diagram (below) indicates the fold change 
of the LC3II band as measured by densitometry (N = 3; **p < 0.005 vs. control; Student’s t test). 
(E) Immunoblot showing LiCl-mediated partial restoration of autophagy blockade in laforin-
deficient cells. COS7 cells transiently transfected with the control or laforin-knockdown construct 
were treated or not treated with LiCl (10 mM, 24 h), and the level of LC3II was evaluated with 
immunoblotting. The bottom bar diagram shows the fold change in the level of the LC3II band, 
and the top bar diagram represents the fold change in glycogen content under similar conditions. 
Each bar in both figures represents the average of three independent experiments (*p < 0.05, 
**p < 0.005, ***p < 0.0005 vs. control; Student’s t test). The densitometric values (fold change) of 
the laforin-specific band (normalized for tubulin) are listed below B and E (identified by an asterisk).
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laforin-knockdown construct and dominant-negative SGK1. As 
shown in Figure 6B, coexpression of dominant-negative SGK1 was 
able to significantly enhance autophagic flux even in laforin-defi-
cient cells, suggesting that wild-type SGK1 is an inhibitor of the 
autophagic process. Taken together, our results suggest that the 
autophagic defects in LD tissues could be due to activation of 
SGK1.
DISCUSSION
The laforin and malin complex appears to function at more than one 
step in regulating glycogen metabolism. For example, a role for 
laforin in removing erroneously added phosphate during the glyco-
gen synthesis process has been proposed, and therefore loss of 
laforin could result in hyperphosphorylated glycogen in LD tissues 
(Tagliabracci et al., 2011), although the specific reason for the same 
in malin-deficient mice (Turnbull et al., 2010) is not yet established. 
Suppression of PTG—a regulatory subunit of protein phosphate 
1—prevented the formation of Lafora bodies in laforin-deficient 
mice (Turnbull et al., 2011a), although why did these animals had 
normal form of glycogen was not well understood, as these double 
mutants should have favored the synthesis of abnormally hyper-
phosphorylated glycogen since they lack laforin. In the present 
study, we extended our previous finding of laforin- and malin-regu-
lated glycogen metabolism at the level of glucose uptake and show 
that the SGK1 could be the connecting link between the LD proteins 
and glycogen accumulation. It is intriguing to note that a majority of 
Lafora bodies in muscle are present in fast-twitch (type II) muscle fi-
ber (Turnbull et al., 2011b), a site that shows predominant SGK1 
expression (Andres-Mateos et al., 2013).
p70S6K phosphorylation level. As shown in Figure 5C, both treat-
ments led to a significant reduction of phospho-p70S6K level even 
in the absence of laforin. Cumulatively these observations suggest 
that activation of mTOR in laforin-deficient cells is suppressed 
by restricting cellular glucose availability, and therefore increased 
cellular glucose level could be a contributing factor toward mTOR 
activation in laforin-deficient cells.
Overexpression of dominant-negative SGK1 inhibits mTOR 
activity and restores autophagy defects in laforin-deficient 
cells
With the observation that cellular glucose levels modulate mTOR 
activity and that inhibition of SGK1 suppresses excessive glucose 
uptake in laforin-deficient cells, we were next interested in testing 
whether suppression of SGK1 activity would inhibit mTOR activity 
in laforin-deficient cells. Therefore the phospho-p70S6K level was 
evaluated in cells transfected with laforin-knockdown construct and 
a construct that codes for the dominant-negative SGK1. As shown in 
Figure 6A, dominant-negative SGK1 significantly reduced phospho-
rylation of p70S6K in laforin-deficient cells, as well as in control cells, 
suggesting the existence of a positive feedback loop between SGK1 
and mTOR activity. In this regard it is interesting to note that a very 
similar mechanism was proposed in diabetic glomeruli, in which en-
hanced expression of Glut1 resulted in mTOR activation (Buller 
et al., 2011).
To evaluate the therapeutic potential of SGK1 inhibition in LD, 
we next checked whether inhibition of SGK1 would also rescue the 
autophagy defect in the laforin-deficient condition. We measured 
the level of LC3II by immunoblotting in cells that expressed the 
FIGURE 5: mTOR activation in the absence of laforin is glucose dependent. (A) Cellular ATP content was measured in 
COS7 cells transfected with either the control or laforin-knockdown construct, and the fold change is presented in the 
top bar diagram. Similarly, the relative levels of phospho (Thr-172) AMPK and its total form were evaluated by 
immunoblotting (bottom) in cells transfected with a knockdown construct for laforin or a control vector, and the relative 
ratio is plotted as a bar diagram (middle). (B, C) Phospho and total levels of p70S6K were estimated by immunoblotting 
in lysates of cells that were transiently transfected with laforin-knockdown construct or a nonsilencing control construct 
and grown in the presence of absence of glucose (B) or upon treatment either cytochalasin B or 2-deoxy glucose (2DG) 
for 12 h (C), as indicated. The bar diagrams (top) show the fold difference in the phospho form as measured by 
densitometry analysis of the signal (N = 3, **p < 0.005, ***p < 0.0005 vs. control; Student’s t test). The densitometric 
values (fold change) of the laforin-specific band (normalized for tubulin) are listed below A and B (identified by an 
asterisk).
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SGK1 in malin-deficient cells needs to be 
studied further.
There are at least two possible ways by 
which the loss of laforin could activate the 
SGK1: 1) a direct mechanism, in which lafo-
rin acts as an SGK1 phosphatase, and 2) an 
indirect mechanism, in which loss of laforin 
activates one of the upstream kinases of 
SGK1. The first possibility does not seem 
likely since we could not observe an interac-
tion between laforin and SGK1 in our pull-
down assays. However, in accordance with 
the second possibility, we found that mTOR 
is a likely link between SGK1 and laforin. 
Our observations that mTOR inhibition sup-
presses SGK1 activity and, conversely, that 
dominant-negative SGK1 inhibits mTOR ac-
tivity suggest the existence of a feedforward 
loop between SGK1 and mTOR in laforin-
deficient cells; the activation of one results 
in the activation of the other. PI3K signaling 
is known to regulate glucose/glycogen me-
tabolism (Ueki et al., 1998; Farese, 2001), 
and AKT is one of its targets (Alessi et al., 
1996). Because no change in the total level 
or in the Ser-473 phospho level of AKT was 
observed in the laforin-deficient mice (Puri 
et al., 2009), malin-deficient mice (DePaoli-
Roach et al., 2012), or cell lines upon knock-
down of laforin or malin (Supplemental 
Figure S1D), we hypothesize that SGK1 and 
mTOR activation might occur through a 
PI3K-independent pathway. Note that intra-
cellular calcium ions (Imai et al., 2003; Gulati 
et al., 2008; Lang et al., 2013) and the small GTPase Rac1 (Shelly 
and Herrera, 2002; Saci et al., 2011) activate both SGK1 and mTOR. 
Conversely, SGK1 regulates calcium signaling as well (Lang et al., 
2013). Therefore it will be of interest to see whether these two sig-
naling cascades are altered in LD tissues.
mTOR is a serine/threonine kinase and a central component of 
nutrient-sensitive signal pathways that regulate several cellular pro-
cesses, such as cell growth and metabolism (Wullschleger et al., 
2006; Laplante and Sabatini, 2012). For example, mTOR directly 
regulates the expression of nesfatin-1, a peptide hormone that sup-
presses appetite and the production of body fat in mammals (Li 
et al., 2012). mTOR exists as two distinct complexes: mTOR com-
plex 1 (mTORC1) and mTORC2. These two complexes are distin-
guished by unique accessory proteins—raptor in mTORC1, and 
rictor in mTORC2 (Laplante and Sabatini, 2012)—and their sensitiv-
ity toward rapamycin, with mTORC1 being more sensitive than 
mTORC2 (Laplante and Sabatini, 2012). mTORC1 activity is regu-
lated by input from various signals, including the growth factor, nu-
trient (glucose and amino acids), and energy. For example, nutrient 
deprivation stabilizes the interaction between mTOR and raptor, 
resulting in inhibition of mTORC1 (Kim et al., 2002), and, conversely, 
glucose availability and higher glycolytic flux trigger Rheb, an adap-
tor protein, to bind and activate mTORC1 (Lee et al., 2009). 
Although abnormal mTOR activation is known in laforin-deficient 
mice (Aguado et al., 2010), the specific signal that activates mTOR 
in laforin-deficient state was not elucidated. We show here that re-
stricting glucose availability or inhibiting glycolytic flux reduces 
mTOR activity. Therefore excessive glucose is likely to be one of the 
SGK1, a gene originally discovered to be induced by serum and 
glucocorticoids in tumor cells (Firestone et al., 2003), is one of the 
downstream players in the PI3K signaling cascade and regulates the 
cell surface localization and function of several metabolite transport-
ers and ion channels (Lang et al., 2006; Lang and Shumilina, 2013). 
For example, SGK1 activates glucose transporters SGLT1, GLUT1, 
and GLUT4 via phosphorylation and by targeting them to the plasma 
membrane (Palmada et al., 2006; Jeyaraj et al., 2007). It was also 
shown that SGK1-regulated cellular glucose uptake is salt sensitive 
(Boini et al., 2006). The activity of SGK1 is regulated by the serum 
growth factor and insulin via their downstream target kinases such 
as PDK1 and mTOR, which are known to phosphorylate SGK1 
(Kobayashi and Cohen, 1999; Park et al., 1999; Garcia-Martinez and 
Alessi, 2008; Hong et al., 2008). Our observations that suppression 
of SGK1 prevented the plasma membrane targeting of glucose 
transporters, excessive glucose uptake, and glycogen accumulation 
upon loss of laforin suggest that SGK1 activation in laforin-deficient 
cells might underlie some of these metabolic changes. Intriguingly, 
suppression of SGK1 did not show any such effect in the malin-defi-
cient condition, although SGK1 appeared to be overactive upon 
loss of malin. One possible explanation is that the process of activa-
tion of SGK1 could be different upon loss of malin as compared with 
loss of laforin. For example, the activity of SGK1 also depends on its 
subcellular localization (Firestone et al., 2003). Thus loss of malin 
may alter the subcellular localization of SGK1 in addition to its activ-
ity, and the approaches used in the present study to suppress SGK1 
might be ineffective in its new environment. This suggestion, how-
ever, is purely speculative, and the cellular process that activates 
FIGURE 6: Dominant-negative SGK1 restores the autophagic defect seen in the laforin-deficient 
state. (A) Immunoblot showing the relative levels of phospho and total p70S6K in COS7 cells 
transfected with the dominant-negative SGK1 (SGK-DN) and the knockdown construct as 
indicated. The bar diagram (top) depicts the fold change in the ratio of phospho to total p70S6K 
levels in respective lanes and plotted with respect to the control (densitometry analysis from 
three independent sets; *p < 0.05, Student’s t test). (B) Immunoblot showing the relative levels 
of LC3II species (arrowhead) in COS7 cells transfected with knockdown constructs with or 
without dominant-negative SGK-DN. Tubulin served as loading control. Each bar represents the 
average of three independent experiments (*p < 0.05; Student’s t test). The densitometric 
values (fold change) of the laforin-specific band (normalized for tubulin) are listed below A and B 
(identified by an asterisk).
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littermates were generously provided by Kazuhiro Yamakawa 
(RIKEN Brain Science Institute, Wako, Japan).
Immunoblotting and antibodies
Immunoblotting was done essentially as described previously (Singh 
et al., 2012a). In brief, after transfer of protein onto a nitrocellulose 
membrane (MDI, Ambala, India), it was blocked with either a 5% 
solution of nonfat dry milk powder (G-Biosciences, St. Louis, MO) or 
bovine serum albumin (Sisco Research Laboratories, Mumbai, India) 
in 1× Tris-buffered saline and Tween 20 for 1 h. Subsequently, the 
membrane was probed with primary antibody, followed by second-
ary antibody tagged with horseradish peroxidase as recommended 
by the manufacturer. Proteins were visualized using a chemilumines-
cent detection kit (SuperSignal West PICO; Pierce, Rockford, IL). The 
following antibodies were used: anti-Myc and anti–green fluores-
cent protein were from Roche India (Mumbai, India); anti-Glut1, anti-
SGK1, and anti–phospho (Thr-256) SGK1 were from Millipore India 
(Bangalore, India); anti-LC3, anti-AKT, anti-phospho (Ser-473) AKT, 
anti-p70S6K, anti–phospho (Thr-389) p70S6K, anti-AMPK, anti–
phospho (Thr-172) AMPK, and anti-caveolin were from Cell Signal-
ing Technology (Danvers, MA). The anti-tubulin antibody was from 
Sigma-Aldrich India. Anti-laforin antibody was described in previous 
studies (Puri et al., 2009; Singh et al., 2012a). Secondary antibodies 
were from Jackson ImmunoResearch (West Grove, PA).
PCR and semiquantitative PCR
Semiquantitative PCR to check the efficiency of malin-knockdown 
plasmid was done essentially as detailed earlier (Singh et al., 2012a). 
For PCR-based genotyping of laforin-deficient animals, the follow-
ing primers were used: forward (for both genotypes), 5′-GCATCG-
GCTGTAAGTTAGCC-3′; reverse (wild type), 5′-CGTGTGTCCAT-
TCTCCAGAA-3′; reverse (knockout allele), 5′-AGCGTATTCAATAAC-
CCTTAAT-3′, using a multiplex reaction. Amplification from the wild-
type allele produces a 620–base pair fragment, and the knockout 
allele produces a 430–base pair fragment.
Plasma membrane fractionation
Plasma membrane fractionation was performed essentially as de-
scribed previously (Singh et al., 2012a). Briefly, cells were harvested 
at 36 h posttransfection, and after washing twice with phosphate-
buffered saline, the cells were incubated in a detergent-free cell lysis 
buffer (10 mM Tris, pH 7.5, 137 mM NaCl, 2 mM phenylmethylsulfo-
nyl fluoride) including a cocktail of phosphatase and protease inhibi-
tors. The cells were kept on ice for 10 min and mildly sonicated. The 
cell lysate was cleared by low-speed centrifugation as 12,000 × g for 
5 min, and a small aliquot of the supernatant was saved as the total 
cell lysate. The supernatant was then subjected to ultracentrifuga-
tion at 100,000 × g (Sorvall MTX 150 microultracentrifuge; rotor 
S55-S) for 1 h. The final pellet fraction, enriched in membrane pro-
teins, was washed twice with lysis buffer and then resuspended in 
lysis buffer containing 1% Triton X-100.
Glucose uptake assay
This was done essentially as described previously (Singh et al., 
2012a). The cells were incubated with Krebs–Ringer–4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffer for 2 h and 
then in 100 μM 2-NBDG (Invitrogen) for 10 min at 37°C. The cells 
were then washed and lysed, and a small aliquot was saved for 
protein estimation (Bradford method). The fluorescence intensity 
in the remaining cell lysate was measured using a fluorescence 
spectrometer (LS 55; Perkin Elmer-Cetus). Nonspecific fluores-
cence was determined by measuring the fluorescence intensity of 
triggers that activate mTORC1 in laforin-deficient cells. Consider-
ing the fact that mTORC1 is a critical regulator of protein transla-
tion, it would be interesting to see whether mTOR regulates the 
function of LD proteins in posttranscriptional gene regulation 
(Ganesh et al., 2000; Singh et al., 2012b).
The activation of mTROC1 was proposed to cause the au-
tophagic defects in laforin-deficient mice (Aguado et al., 2010). 
However, we found that the autophagy defect in the laforin-defi-
cient condition is perhaps mTOR independent, as it is not rescued 
by rapamycin treatment. This is supported by the observation made 
in malin-deficient mice, in which autophagy defects are seen with-
out any alteration in mTOR activity (Criado et al., 2012). This was 
strengthened by our observation that lithium treatment, which acti-
vates autophagy via an mTOR-independent pathway, restored au-
tophagic blockade in laforin-deficient cells. Lithium inhibits inositol 
monophosphatase to deplete the free inositol level (Sarkar et al., 
2005). Of interest, hyperglycemia-induced uptake of inositol has 
been found in rat mesangial cells (Guzman and Crews, 1992), and 
therefore it is possible that a similar mechanism might operate in LD 
and contribute to autophagy defects. Our demonstration that the 
autophagy defect does not lead to glycogen accumulation in lafo-
rin-deficient cells suggests that mTOR activation, autophagy defect, 
and glycogen accumulation are independent outcomes of laforin 
deficiency. Similarly, our demonstration that partial suppression of 
SGK1 restores the autophagic process and suppresses mTOR activ-
ity in laforin-deficient cells reveals a novel function for SGK1 and 
that these defects could be secondary to the activation of SGK1 in 
LD tissues. While this article was being written, Andres-Mateos 
et al. (2013) documented that the activation of starvation-induced 
autophagy is compromised in a transgenic mice line that over-
expressed constitutively active SGK1, which independently estab-
lished a critical role for SGK1 in autophagy induction. Taken 
together, our findings propose that suppression of SGK1 could be 
an effective therapeutic approach to suppressing glycogen accu-
mulation, inhibiting mTOR activity, and rescuing autophagy defects 
in LD. Given that SGK1 inhibitors are known (Ackermann et al., 
2011), it would be of significance to test their therapeutic potential 
in LD animal models.
MATERIALS AND METHODS
Cell culture, transfection, expression constructs, 
and animal models
COS7 cells were obtained from the American Type Cell Culture 
(ATCC, Manassas, VA) and grown in DMEM (Sigma-Aldrich India, 
Bangalore, India) with 25 mM of glucose and 10% (vol/vol) fetal 
calf serum (HyClone, Logan, UT). Transfection was done using Tur-
bofect (Thermo Fisher Scientific India, Mumbai, India) as recom-
mended by the manufacturer. All of the chemicals were purchased 
from Sigma-Aldrich India unless stated otherwise. The mammalian 
expression constructs used for the expression of wild type or the 
mutant forms of laforin, malin, and the glucose transporters were 
described previously (Singh et al., 2012a). The expression con-
struct that codes for the dominant-negative SGK1 mutant (Amato 
et al., 2009) was generously provided by Nicola Perrotti (University 
Magna Graecia, Catanzaro, Italy). The shRNA knockdown con-
structs for laforin, malin, and the control nonsilencing RNAi vector 
were purchased from Open Biosystems (Katy, TX) and were vali-
dated in our previous studies (Garyali et al., 2009; Sengupta et al., 
2011; Singh et al., 2012a,b). The shRNA construct for the knock-
down of SGK1 was a gift from Eminy H. Y. Lee (Institute of 
Biomedical Sciences, Academia Sinica, Taipei, Taiwan). Skeletal 
muscle tissues of the laforin-knockout mice and their wild-type 
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cells treated with an inhibitor of glucose uptake, cytochalasin B 
(50 μM). Fluorescence intensity was normalized based on protein 
content, and the data are presented as the fold change.
Glycogen measurement
To measure cellular glycogen levels, cells were scraped in ice-cold 
30% KOH and lysed by heating the suspension to 100°C for 20 min. 
A small aliquot of the lysate was saved for protein estimation, and 
the rest was spotted onto filter paper (Whatman 31-ET CHR). This 
paper was first washed in ice-cold 66% ethanol for 10 min, followed 
by two more washes in the same solution at room temperature, and 
the membrane was kept at 37°C overnight for drying. To digest gly-
cogen, the membrane was incubated in an amyloglucosidase solu-
tion (0.5 mg/ml in 0.02 M sodium acetate, pH 4.8) for 2 h at 37°C. 
The released glucose was measured, and the quantity of glycogen 
was expressed as amount of released glucose per milligram of total 
protein.
Statistical analysis
Experiments were repeated at least in triplicate. Data were analyzed 
by two-tailed, unpaired Student’s t test using GraphPad (La Jolla, CA) 
software. Differences were considered significant at p < 0.05 and 
denoted by *p < 0.05, **p < 0.005, and ***p < 0.0005, respectively.
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